Tengborn L, Hansson S, Fasth A, Lübeck P O, Berg A, Ljung R
Department of Internal Medicine, Sahlgrenska University Hospital, Göteborg, Sweden.
Haemophilia. 1998 Nov;4(6):854-9. doi: 10.1046/j.1365-2516.1998.00190.x.
Anaphylaxis/anaphylactoid reactions have recently been reported after few treatments with factor IX concentrates in patients with haemophilia B at the same time as inhibitors to factor IX were demonstrated. In some of these cases nephrotic syndrome has appeared during immune tolerance induction (ITI) with high doses of factor IX concentrates. Gene deletions seem to be associated with a high risk of developing antibodies to factor IX. This report presents two brothers with deletion of 1 bp in exon f of the factor IX gene. Both showed anaphylactoid reactions and they were desensitized using slow i.v. injections of factor IX. At the time of anaphylaxis, inhibitors of factor IX in a low titre could be demonstrated. The elder brother responded well after a short time on ITI and has no spontaneous bleedings on regular prophylaxis although in a somewhat higher dose than expected. On the other hand, in spite of comparable regimens, the younger brother has so far been resistant to ITI. Moreover, during treatment with extremely high doses of factor IX concentrate he developed nephrotic syndrome which only slowly subsided after treatment with corticosteroids and withdrawal of factor IX.
近期有报道称,在B型血友病患者使用凝血因子IX浓缩物进行少量治疗后,出现了过敏反应/类过敏反应,同时还检测到了凝血因子IX的抑制物。在其中一些病例中,在使用高剂量凝血因子IX浓缩物进行免疫耐受诱导(ITI)期间出现了肾病综合征。基因缺失似乎与产生凝血因子IX抗体的高风险相关。本报告介绍了两名兄弟,他们的凝血因子IX基因外显子f缺失1个碱基对。两人均出现类过敏反应,并通过缓慢静脉注射凝血因子IX进行脱敏治疗。在发生过敏反应时,可检测到低滴度的凝血因子IX抑制物。哥哥在进行ITI治疗短时间后反应良好,在常规预防治疗期间没有自发性出血,尽管所用剂量略高于预期。另一方面,尽管治疗方案相似,但弟弟迄今为止对ITI治疗有抵抗性。此外,在使用极高剂量的凝血因子IX浓缩物治疗期间,他出现了肾病综合征,在使用皮质类固醇治疗并停用凝血因子IX后,肾病综合征才缓慢消退。